Keloids are one of the more frustrating problems in dermatology. They are raised, often itchy, sometimes painful overgrowths of scar tissue that extend beyond the boundary of the original wound, and their defining clinical feature is that they come back. Cut one out and there is a substantial chance a new one grows in its place.
In 2026 a group published the first randomized trial of hydrogen-rich water in keloid patients[1]. It is a genuinely interesting study and it is also much smaller and much narrower than the headline suggests. This page covers what it did, what it found, and the one thing it did not measure that matters most.
What the trial actually did
Twenty-one keloid patients who were already scheduled for two-stage operations were randomly divided into a hydrogen-rich water group and a control group. The hydrogen group received hydrogen in their drinking water; the control group drank hydrogen-free water[1]. The study was double-blinded, which for a trial resting heavily on self-reported symptoms is the right design choice and is worth crediting.
Two categories of outcome were collected. The first was clinical: the frequency of pain and pruritus, meaning itch, and scores on the Vancouver Scar Scale along with its pigmentation domain. The second was laboratory: cytokines related to inflammation, keloid formation and symptoms, measured by western blotting, qPCR and ELISA before and after the intervention[1].
Note the population. Every participant was already booked in for surgery. Nobody in this trial avoided an operation, and the study was not designed to find out whether anyone could have.
What it found
Patients reported a significantly lower frequency of pain and itch after hydrogen-rich water therapy. Vancouver Scar Scale scores and the pigmentation domain scores significantly decreased[1].
On the laboratory side, the expression of TRPV1, a cytokine related to itch, and HIF-1 alpha, related to keloid formation, both significantly decreased. The anti-inflammatory cytokine IL-10 increased, while VEGF and TGF-beta, both inflammation-related, decreased[1].
Those molecular results are the more interesting half, because they are not self-reported. TGF-beta in particular is not an arbitrary choice of marker. It sits close to the centre of how keloids are currently understood to form, and reviews of keloid pathogenesis treat the TGF-beta signalling pathway as a principal driver of the excessive collagen deposition that defines the disorder[2]. Chronic inflammation is likewise treated as a core mechanism rather than a side effect in keloid and hypertrophic scarring[3].
So the pattern is coherent: the reported symptom improvement moved in the same direction as markers that keloid biology says should matter. Coherence is not proof, but it is better than an isolated symptom score with no mechanism behind it.
The number this trial does not contain
Here is the part that has to be said plainly. The published abstract asserts that these changes were significant, and it does not report a single p-value, confidence interval or effect size for any outcome[1].
That means there is currently no number from this trial that anyone can honestly quote. Not for pain, not for itch, not for the scar scale, not for any of the cytokines. This page therefore quotes none, and you should be sceptical of any article about hydrogen water and keloids that does contain such numbers, because they did not come from this abstract.
“Significant” without a magnitude also leaves the practical question open. A statistically significant reduction in itch frequency in twenty-one people could be a change that patients would describe as life-improving, or one they would struggle to notice. The abstract does not let you tell the difference.
The endpoint that is missing
This is the substantive limitation, more important than the sample size.
The trial measured symptoms, a scar-appearance scale and cytokines. It did not report whether the keloids got smaller, and it did not report whether they recurred. Recurrence after excision is the central clinical problem of keloid disease and the reason keloid management is difficult at all[2]. A therapy that reduces itch is worth having. A therapy that reduces recurrence would change practice. This study speaks to the first and is silent on the second.
The authors are not overselling it either. They describe the work as exploratory, call it a pilot trial, and frame the findings as early clinical signals supporting further large-scale investigation[1]. That is an honest summary and it is the one to carry away.
Twenty-one people
Twenty-one participants split into two groups means roughly ten per arm. At that size, a trial can detect only large effects, and estimates of how large the effect is are very imprecise. It also means the two groups can differ by chance in ways that randomisation would even out in a larger study.
The correct reading of a positive result in a ten-per-arm pilot is not “this works”. It is “this is worth testing properly”. Those are different claims and the gap between them is where most supplement marketing lives.
Why hydrogen at all
The rationale is not arbitrary. The foundational work on molecular hydrogen reported that it acts as a selective antioxidant, reacting with hydroxyl radical, one of the most damaging reactive oxygen species, while leaving useful signalling molecules alone[4]. Since keloid formation involves a sustained inflammatory and oxidative environment[3], an agent that dampens that environment without shutting down normal redox signalling is a reasonable thing to try.
Reasonable rationale is where research starts, not where it ends. Plenty of biologically sensible interventions fail in adequately sized trials.
What this means if you have keloids
Nothing here justifies replacing anything. Established keloid management, including intralesional steroid injection, surgical approaches and the other options covered in the clinical literature[2], is supported by far more evidence than one twenty-one person pilot.
If you already drink hydrogen water, this study is mildly encouraging on the symptom side and gives no reason to stop. If you do not, this is not a strong enough result to start on its own, and it certainly is not a reason to delay seeing a dermatologist about a keloid that is growing, painful or in a location that will be difficult to treat later.
The one thing worth saying to a clinician is that itch and pain are legitimate treatment targets in their own right, independent of whether the keloid shrinks. If those symptoms are what actually bothers you, say so, because they are treatable through several routes and the conversation tends to default to appearance instead.
The bottom line
A double-blinded randomized pilot trial in twenty-one keloid patients awaiting surgery reported significantly reduced pain and itch frequency, significantly reduced Vancouver Scar Scale and pigmentation scores, and cytokine shifts consistent with less inflammation, after drinking hydrogen-rich water[1].
No p-values or effect sizes were published, so nothing from it is quotable as a number. It did not measure keloid size or recurrence, which is the outcome that would matter most. The authors call it exploratory and ask for larger studies, and that is exactly the right place to leave it.
For context on how molecular hydrogen is thought to work at all, see our page on the selective antioxidant mechanism, and for the broader picture on inflammation see hydrogen water and inflammation.
References
- Exploratory Evaluation of Hydrogen-Rich Water Therapy for Keloid Management: A Double-Blinded Randomized Pilot Trial. Aesthetic Plastic Surgery, 2026
- Comprehensive Insights into Keloid Pathogenesis and Advanced Therapeutic Strategies. International Journal of Molecular Sciences, 2024
- The Roles of Inflammation in Keloid and Hypertrophic Scars. Frontiers in Immunology, 2020
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine, 2007
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
